ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Comparison of Cephalexin and Ciprofloxacin Prophylaxis for Urinary Tract Infection in Kidney Transplant Recipients

N. A. Pauley, M. Fitzmaurice, A. Poparad-Stezar, B. Summers, A. Jantz

Transplant Institute, Henry Ford Hospital, Detroit, MI

Meeting: 2022 American Transplant Congress

Abstract number: 1007

Keywords: Infection, Kidney, Kidney transplantation, Prophylaxis

Topic: Clinical Science » Infection Disease » 25 - Kidney Infectious Non-Polyoma & Non-Viral Hepatitis

Session Information

Session Name: Kidney Infectious Non-Polyoma & Non-Viral Hepatitis

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Compare efficacy and safety outcomes of patients (pts) that received alternative agents as prophylaxis (ppx) for urinary tract infection (UTI) after kidney transplant (KT) as there is limited data available in those intolerant to the first-line agent sulfamethoxazole-trimethoprim (S/T).

*Methods: This single-center, retrospective analysis evaluated pts who received cephalexin 500mg (CLX) or ciprofloxacin 500mg (CIP) daily for UTI ppx. Requirement for inclusion was > 30 consecutive days of therapy within 6 months post-KT in pts intolerant or allergic to S/T. The primary efficacy endpoint was ppx failure defined as clinically relevant UTI (Table 1). Secondary efficacy outcomes were UTI characteristics, change in renal function, development of resistance, and graft loss. Safety outcomes included adverse effects (ADE), discontinuations, or hospital visits.

*Results: 78 pts were included, 39 per group. Total days of therapy were 150 + 40 and 155 + 49 for CLX and CIP (p=0.315). There were no differences in baseline characteristics (See Table 2) except younger age (p=0.046) in the CLX group. Baseline creatinine clearances (CrCl; Cockcroft-Gault) were 59.7 [45.3-74.3] & 49.5 mL/min [38.3-64.0] (CLX vs CIP; p=0.05). Pts in the CLX group experienced more UTIs (CLX vs CIP: 14 (36%) vs 7 (18%); p=0.085), although the incidence did not reach statistical significance. Pts in the CLX group had more cystitis and treated bacteriuria but had significantly more post-operative complications (p=0.044). While there was a significantly lower CrCl at day 180 in the CIP group of 48.3 [34.9-59.5] vs 60.5 mL/min [44.1-71.0] (p=0.016), no difference was seen in change from baseline to day 180 (p=0.924). No significant difference was seen in the total occurrence of ADEs (p=0.817), but more pts discontinued CIP therapy (15% vs 5%; p=0.125). Development of antimicrobial resistance was similar and there was no difference in hospital visits or graft loss.

*Conclusions: Both CLX and CIP were effective at providing UTI ppx post-KT. Pts who received CLX had a higher incidence of UTIs, potentially due to more post-operative complications observed. Although CIP was discontinued more frequently, both agents were overall well tolerated while maintaining similar outcomes in renal and graft function. Overall, CLX is a suitable alternative for UTI prophylaxis in those unable to use S/T to prevent unnecessary fluoroquinolone exposure.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Pauley NA, Fitzmaurice M, Poparad-Stezar A, Summers B, Jantz A. Comparison of Cephalexin and Ciprofloxacin Prophylaxis for Urinary Tract Infection in Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-cephalexin-and-ciprofloxacin-prophylaxis-for-urinary-tract-infection-in-kidney-transplant-recipients/. Accessed May 17, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences